Medical device sponsors often prepare for inspections with confidence. They follow ISO 14155, maintain technical documentation, and manage risk according to ISO 14971.
Yet inspection feedback increasingly sounds unfamiliar:
The authority asks about oversight rationale.
They question monitoring focus.
They expect traceability of decisions, not only documentation of activities.
For many MedTech teams, the reaction is confusion:
We followed device regulations, why are we being assessed like a pharma trial?
Over the last few years, BioPharma guidance has become explicit. ICH E6(R3) describes a structured quality approach based on critical risks, ongoing evaluation, and documented reasoning.
Medical device regulations did not adopt the same vocabulary. However, EU MDR, ISO 14155, and post-market requirements increasingly demand the same behavior: Not activity-based compliance, but demonstrable control.
This means inspectors no longer primarily verify whether tasks were performed. They assess whether decisions were justified.
The difference is subtle, but operationally fundamental.
Inspection observations across device investigations now frequently relate to:
unclear sponsor oversight
monitoring not linked to risk
incomplete reconstruction of decisions
insufficient justification of deviations
fragmented data traceability
None of these topics explicitly mention Risk-Based Quality Management. Yet all of them evaluate what RBQM produces.
In other words:
Device regulations describe documentation structures, while inspections evaluate oversight logic.
This is where friction arises.
Teams comply with the written regulation but are assessed against an implicit operating model.
BioPharma expresses quality through a structured framework:
Quality by Design defines what matters. RBQM determines how it is overseen. Documentation demonstrates why decisions were made.
MedTech expresses quality differently:
State-of-the-art planning defines intended performance. Risk management structures the lifecycle. Technical documentation shows conformity.
The terminology differs.
The expected behavior does not.
Both converge toward the same inspection question:
Can you explain, using evidence, why you acted the way you did?
This convergence creates an internal alignment problem.
Clinical teams speak in terms of monitoring and protocol deviations. Quality teams speak in terms of non-conformities and CAPA.
CROs reference RBQM processes. Manufacturers rely on risk files and technical documentation.
Everyone describes the same reality using different languages.
As a result, collaboration becomes slower, oversight becomes inconsistent, and inspection readiness becomes reactive rather than planned.
The issue is not missing compliance.
It is missing translation.
To address this gap, we created a practical alignment resource:
Clinical Quality Translation Guide: BioPharma ↔ MedTech
Instead of summarizing regulations, it maps equivalent operational concepts across sectors, showing how identical expectations appear under different names.
It allows QA, Clinical, Operations, and partners to align discussions before audits force the alignment. Because increasingly, inspections assume this shared understanding already exists.
MedTech is now inspected like Pharma, only the vocabulary is different.
MedTech is now inspected like Pharma, only the vocabulary is different.
Organizations that recognize this convergence early begin to change how they approach compliance. Rather than viewing it as the completion of documentation, they start to treat it as the traceability of decisions over time.
The effect goes beyond inspection confidence. Monitoring effort becomes more focused, deviation handling more consistent, and vendors operate under shared expectations. Oversight, in turn, becomes scalable across investigations.
The regulatory burden does not increase, but the clarity does.
Regulators have not formally merged BioPharma and MedTech frameworks; instead, they have aligned the outcomes they expect to see in practice.
As a result, device investigations are now evaluated against behaviors historically associated with RBQM, whether or not that terminology is used. Teams that introduce a translation layer between these worlds tend to operate predictably, while those that do not often encounter recurring “unexpected” findings.
To support internal alignment across QA, Clinical, and partners, we prepared a concise working reference. Use it to align terminology, expectations, and oversight logic before the next inspection requires it.
Many device teams already perform the right activities, but under different terminology. We help translate ISO 14155 and MDR expectations into a clear operational model so QA, Clinical, and CRO partners work from the same understanding.
Start with a short discussion focused on your current investigation setup and where inspection friction typically appears.
Featured Insights
Start Your Roll-Out
Quick Answers
Guest Speaker
Brian Barnes
BioNTech
Presented By
Dr. Johann Proeve
Cyntegrity
Presented By
Keith Doricott, MBB
Dorricott Metrics
Unlock AI-powered RBQM, understand its impact, and put it to work in your processes today.
Date
11 March 2026
